Corcept Therapeutics shares are trading lower after the company announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept's U.S. Patents 10,195,214 and 10,842,800.
Benzinga Newsdesk - Jan 2, 2024, 8:42AM